0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV58.63%PremiumFeb 21, 2025Expiry Date0.00Intrinsic Value100Multiplier64DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Forte Biosciences Stock Discussion
News/update on their R&D on 3rd December 2024, Phase 1 top-line result by the second quarter of 2025. They have cash available which will sustain the company operations for 12 months (exclude the recent oversubscribed private placement 53mil)
No comment yet